Clinical Trials Logo

Clinical Trial Summary

Aspirin-Exacerbated Respiratory Disease (AERD), although uncommon in the general population, is an important phenotype of severe asthma and nasal polyposis where it occurs in 15% of severe asthmatics, and up to 30% of those with nasal polyposis. An important therapy for AERD is aspirin therapy after desensitization (ADAT). This is an inexpensive and proven therapy to improve the burden of sinus disease in AERD. Aspirin desensitization is the mechanism by which tolerance is induced in AERD patients. This is a 1-2 day outpatient procedure whereby increasing doses of aspirin are administered and the patients invariably experience some degree of hypersensitivity reactions. It is important to understand the effect of medications on the aspirin desensitization. It is known that the leukotriene modifier medications decrease the severity of the reactions in AERD. Other treatments such as antihistamines and the biologic agent omalizumab might have an effect on either blocking or blunting reactivity in AERD during desensitization. Dupilumab is a new respiratory biologic approved for atopic dermatitis, eosinophilic asthma and nasal polyposis. As such, it is well situated to be used for many AERD patients whose disease cannot be well controlled. The effect of dupilumab on the aspirin desensitization process and reaction is unknown and is the topic of this investigation. The primary objective is to determine the effect of dupilumab on reactions during aspirin challenge/desensitization.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05031455
Study type Interventional
Source Scripps Clinic
Status Not yet recruiting
Phase Phase 2
Start date January 1, 2022
Completion date February 28, 2025

See also
  Status Clinical Trial Phase
Completed NCT03595488 - Dupilumab for Aspirin-exacerbated Respiratory Disease Phase 2
Enrolling by invitation NCT03627481 - Sleep Quality After Nasosinusal Surgery in AERD Patients N/A
Recruiting NCT03849625 - Characteristics of Patients Diagnosed With NSAID Sensitivity in Thailand
Active, not recruiting NCT03973749 - Effects of a High or Low Salycilate Diet on Urinary LTE4 and Clinical Features in AERD N/A
Recruiting NCT04147013 - Effect of Celecoxib on Postoperative Analgesia and Disease Severity in AERD Patients With CRS Phase 4
Completed NCT01631773 - A Comparison of microRNA Samples in Patients With Nasal Polyps and Aspirin Exacerbated Respiratory Disease and Those With Nasal Polyps Only N/A
Recruiting NCT03326063 - Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban Phase 2